{"schemaVersion":"peptidescanner-peptide-evidence-feed/v1","canonicalUrl":"https://peptidescanner.com/feeds/peptides/motixafortide.json","peptide":{"slug":"motixafortide","name":"Motixafortide","url":"https://peptidescanner.com/peptides/motixafortide/"},"release":{"label":"Beta · 17 Nov 2026","reviewedAt":"2026-11-17"},"entryCount":17,"entries":[{"objectId":"story:clinicaltrials-gov-nct04543071-motixafortide:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT04543071","domain":"Clinical trials","dateInSource":"2026-09-21","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct04543071-motixafortide/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#clinicaltrials-gov-nct04543071-motixafortide-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#clinicaltrials-gov-nct04543071-motixafortide-v1","contentSha256":"217ead00a2cbc4bbc1031217a72bbf1c3614df3c117d007df05488efac3da0b8"},{"objectId":"story:clinicaltrials-gov-nct05618301-motixafortide:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT05618301","domain":"Clinical trials","dateInSource":"2025-08-11","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct05618301-motixafortide/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#clinicaltrials-gov-nct05618301-motixafortide-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#clinicaltrials-gov-nct05618301-motixafortide-v1","contentSha256":"5a5c9429767f6f10283d08f3da027d5150bb03a084df2be24274dec635d98a64"},{"objectId":"story:clinicaltrials-gov-nct06442761-motixafortide:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT06442761","domain":"Clinical trials","dateInSource":"2026-09-08","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct06442761-motixafortide/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#clinicaltrials-gov-nct06442761-motixafortide-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#clinicaltrials-gov-nct06442761-motixafortide-v1","contentSha256":"fd80f201528c172bcfd6710d5d137710c86d1f63a0c7b865b1f0bc0f6f92e87b"},{"objectId":"story:clinicaltrials-gov-nct06506461-motixafortide:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT06506461","domain":"Clinical trials","dateInSource":"2026-10-15","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct06506461-motixafortide/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#clinicaltrials-gov-nct06506461-motixafortide-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#clinicaltrials-gov-nct06506461-motixafortide-v1","contentSha256":"1f6d378479f407ebe35ca942c96612c0fdc9ed2abfd9020bc02f7e80d8a99277"},{"objectId":"story:clinicaltrials-gov-nct06547112-motixafortide:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT06547112","domain":"Clinical trials","dateInSource":"2025-08-29","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct06547112-motixafortide/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#clinicaltrials-gov-nct06547112-motixafortide-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#clinicaltrials-gov-nct06547112-motixafortide-v1","contentSha256":"0d5dd7ddd36ffd4d0836bf7ee82e2926b5fa4fc73777851f10b369702a396e34"},{"objectId":"story:clinicaltrials-gov-nct07101445-motixafortide:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT07101445","domain":"Clinical trials","dateInSource":"2026-07-23","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct07101445-motixafortide/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#clinicaltrials-gov-nct07101445-motixafortide-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#clinicaltrials-gov-nct07101445-motixafortide-v1","contentSha256":"11e820fff698897018694eee1b8736b1f1ed51674e67a9753ab4c27687344adf"},{"objectId":"story:clinicaltrials-gov-nct07392970-motixafortide:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT07392970","domain":"Clinical trials","dateInSource":"2026-07-24","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct07392970-motixafortide/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#clinicaltrials-gov-nct07392970-motixafortide-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#clinicaltrials-gov-nct07392970-motixafortide-v1","contentSha256":"0b0dfd93d2abb8140450502fccb5892ebe93b65ec23f3e910063e97343eac709"},{"objectId":"story:fda-drugs-nda217159:v1","state":"current","stateChangedAt":"2026-11-16","title":"Drugs@FDA application NDA217159","domain":"Regulatory","dateInSource":"2023-09-08","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/fda-drugs-nda217159/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#fda-drugs-nda217159-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#fda-drugs-nda217159-v1","contentSha256":"fcebc83bfc1bd1a00625b0fcc9b7824923afbe0666fd0502b33f27476f821052"},{"objectId":"story:pubmed-pmid-34253578-motixafortide:v1","state":"current","stateChangedAt":"2026-11-16","title":"Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial.","domain":"Literature metadata","dateInSource":"2022-04-01","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-34253578-motixafortide/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-34253578-motixafortide-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#pubmed-pmid-34253578-motixafortide-v1","contentSha256":"6d0b3b75df5b52b4f8eca71c2cd6706c438eaa534e73ffafb19c3e2343eabb68"},{"objectId":"story:pubmed-pmid-36901829-motixafortide:v1","state":"current","stateChangedAt":"2026-11-16","title":"Structural Basis of the Binding Mode of the Antineoplastic Compound Motixafortide (BL-8040) in the CXCR4 Chemokine Receptor.","domain":"Literature metadata","dateInSource":"2023-03-14","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-36901829-motixafortide/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-36901829-motixafortide-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#pubmed-pmid-36901829-motixafortide-v1","contentSha256":"2e305d07d1ca4b5d1fbd6ab054156352894ee7af58d3ff5586a5d0cdbef2f63a"},{"objectId":"story:pubmed-pmid-37069359-motixafortide:v1","state":"current","stateChangedAt":"2026-11-16","title":"Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.","domain":"Literature metadata","dateInSource":"2026-11-09","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-37069359-motixafortide/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-37069359-motixafortide-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#pubmed-pmid-37069359-motixafortide-v1","contentSha256":"499a69353d02f88edc61d315066308670719df2daf837c69031cfe415104f6b2"},{"objectId":"story:pubmed-pmid-37862457-motixafortide:v1","state":"current","stateChangedAt":"2026-11-16","title":"Motixafortide Acetate.","domain":"Literature metadata","dateInSource":"2024-10-09","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-37862457-motixafortide/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-37862457-motixafortide-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#pubmed-pmid-37862457-motixafortide-v1","contentSha256":"e8947914519395f8c74209bfc9e4a69393ea41a6c28bc127018863b53e17e4d3"},{"objectId":"story:pubmed-pmid-38629183-motixafortide:v1","state":"current","stateChangedAt":"2026-11-16","title":"A comparative review of Aphexda and Mozobil for mobilization prior to stem cell collection.","domain":"Literature metadata","dateInSource":"2024-10-30","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-38629183-motixafortide/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-38629183-motixafortide-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#pubmed-pmid-38629183-motixafortide-v1","contentSha256":"d931bc99ffc9065a01e5c125e088c8469c217e8937b397d215276efe9afd87cb"},{"objectId":"story:pubmed-pmid-40420423-motixafortide:v1","state":"current","stateChangedAt":"2026-11-16","title":"Development and Validation of the LC-MS/MS Method and Its Application for Pharmacokinetic Studies for the Simultaneous Estimation of Motixafortide and Filgrastim in rat Plasma.","domain":"Literature metadata","dateInSource":"2025-05-27","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-40420423-motixafortide/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-40420423-motixafortide-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#pubmed-pmid-40420423-motixafortide-v1","contentSha256":"12c915f001bcba800bc08cd4bfd9c7c66a353067b2828c8400f4446d4fe16597"},{"objectId":"story:pubmed-pmid-41741368-motixafortide:v1","state":"current","stateChangedAt":"2026-11-16","title":"Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study.","domain":"Literature metadata","dateInSource":"2026-08-13","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-41741368-motixafortide/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-41741368-motixafortide-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#pubmed-pmid-41741368-motixafortide-v1","contentSha256":"b15bc82980fb1284ba9fda2e53207d2e3e7382fa9e4f21a79a9931871e515ea6"},{"objectId":"story:pubmed-pmid-42435378-motixafortide:v1","state":"current","stateChangedAt":"2026-11-16","title":"Comparative analysis of motixafortide versus plerixafor for stem cell mobilization and collection in multiple myeloma: A single center real-world experience.","domain":"Literature metadata","dateInSource":"2026-07-11","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-42435378-motixafortide/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-42435378-motixafortide-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#pubmed-pmid-42435378-motixafortide-v1","contentSha256":"6dd905b19fad54ce213b224f5e07e46876351e711b2d9ac0199b39c07aa9a463"},{"objectId":"story:pubmed-pmid-42811017-motixafortide:v1","state":"current","stateChangedAt":"2026-11-16","title":"Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives.","domain":"Literature metadata","dateInSource":"2026-11-09","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-42811017-motixafortide/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.json#pubmed-pmid-42811017-motixafortide-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/motixafortide.md#pubmed-pmid-42811017-motixafortide-v1","contentSha256":"61733ba3a1de23184edbf8799c8333842b1e66fc871734801148eefdc2f3d508"}]}
